Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 295

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 295
---
 our proprietary technology in the marketplace.

If
third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual
property, our operating profits could be adversely affected.

We
have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been
granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.

Risks
Related to Our Operations and Financial Condition

We
are an early development-stage company with no revenues and our financial condition raises substantial
doubt as to our ability to continue as a going concern.

Because
we have a limited operating history, you may not be able to accurately evaluate our operations.

We
will need to raise additional financing for the continuation of our operations.

Our
operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues
and succeed overall.

We
have yet to achieve a profit and will not achieve a profit in the near future, if at all.

Certain
of our executive officers are not be employed by us on a full-time basis.

Conflicts
of interest may arise between us and MIRALOGX.

Risks
Relating to Our Business and Our Industry

Our
future success will largely depend on the success of Telomir-1 and any future product candidates, which development will require significant
capital resources and years of clinical development effort.

We
are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.

Results
of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.

We
have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement
capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.

We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.

We
expect to face intense competition, often from companies with greater resources and experience than we have.

We
have significant and increasing liquidity needs and may require additional funding.

20

Risks
Related to Development and Regulatory Approval of Our Product Candidates

Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change,